AI in Clinical Trials Market Report and Forecast 2025-2034

The global AI in clinical trials market was valued at USD 2.05 Billion in 2024, driven by rising requirements to overcome data limitations across the globe. It is expected to grow at a CAGR of 14.00% during the forecast period 2025-2034, and attain a market value of USD 7.60 Billion by 2034.

AI in Clinical Trials Market Overview

AI technology, combined with big data, can tackle major obstacles in clinical trials by processing and examining large volumes of data. AI and advanced analytics can enhance productivity in clinical R&D by merging trial phases, developing patient-focused endpoints, and examining real world data. Increased participation of AI in drug research and development is expected to fuel market growth. Additionally, the market is impacted by the increasing emphasis on diversity and inclusivity.

AI in Clinical Trials Market Growth Drivers

Artificial Intelligence (AI) in Drug Research and Development to Drive Market Growth

Advancements in technology and artificial intelligence are driving growth in the field of drug research and development. A July 2024 update demonstrates how AI and data analytics are reducing time and costs for introducing medications to the market, improving efficiency in clinical trials, managing data complexities, and optimizing technological investments in the biopharmaceutical industry.

AI in Clinical Trials Market Trends

The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:

Rising Focus on Diversity and Inclusivity

Emphasizing diversity and inclusivity is a significant market trend. A study published in October 2024 revealed that 80% of clinical trials encounter challenges in recruiting diverse participants. AI can help address these challenges by improving engagement and inclusivity in clinical trials.

Increasing Collaboration and Partnership

A noteworthy trend in the market is the growing partnership and collaboration among companies. In October 2024, Eli Lilly partnered with Insitro in the AI-driven clinical trials sector. Under this partnership, Insitro will focus on drug discovery, bringing new treatments to market, and will pay royalties to Lilly, signaling a trend towards biotech collaboration and trust in AI firms.

Growing Focus on Overcoming Data Limitations

The use of generative AI in clinical trials, especially for diseases such as acute myeloid leukemia, is a significant trend in the market. Research published in March 2024 on utilizing generative AI for producing artificial patient information for this illness shows increasing possibilities in the AI within the clinical trials market and encouraging broader utilization of AI in clinical trials, resulting in market growth.

Focus on Patient Outcomes and Accessibility

The market is witnessing a trend of increased focus on enhancing patient results and expanding access to advanced treatments by turning clinics into innovation hubs. This is in line with larger patterns in the healthcare industry that focus on putting patients first and providing individualized medical treatments.

AI in Clinical Trials Market Segmentation

The market report offers a detailed analysis of the market based on the following segments:

Market Breakup by Phase:

• Phase I
• Phase II
• Phase III

Market Breakup by Application:

• Oncology
• Neurology Diseases
• Cardiological Diseases
• Infectious Disease
• Immunological Diseases
• Others

Market Breakup by End User:

• Pharmaceutical and Biopharmaceutical Companies
• Academic and Research Institutes
• Cancer Centers
• Others

Market Breakup by Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

AI in Clinical Trials Market Share

Market Segmentation Based on the Application to Witness Growth

Based on the application, the market for AI in clinical trials is segmented into oncology, neurology diseases, cardiological diseases, infectious diseases, immunological diseases, and others. The infectious disease segment is expected to dominate the market share as AI allows for the effective processing and analysis of complex data sets, helping researchers gain new insights and make defensible conclusions in clinical studies.

AI in Clinical Trials Market Analysis by Region

Based on region, the market report covers North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. North America, especially the United States, is at the forefront of AI innovation and technology, leading the AI in clinical trials market. This dominance is driven by the presence of major IT companies, educational institutions, and new startups dedicated to developing and advancing AI technologies for various sectors.

Leading Players in the AI in Clinical Trials Market

The key features of the market report include patent analysis, grant analysis, funding, and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

Unlearn.ai, Inc.

Unlearn.AI is a healthcare AI company that develops AI to speed up drug development and remove trial and error in medicine using digital twins.

Saama

Saama, is a consulting and systems integration firma platform for clinical analytics powered by AI, presents GenAI and collaborative tools to improve data analysis in clinical development.

Antidote Technologies, Inc.

Antidote is a digital health company that employs artificial intelligence and digital technologies to improve the recruitment of participants for clinical trials, helping medical research by effectively linking patients with trials, thereby decreasing delays and expenses and ultimately benefiting the global AI in clinical trials market.

Phesi

Phesi, a United States-based company specializing in data infrastructure and analytics for clinical trials, provides AI-based data solutions through their trial accelerator™ platform to enhance trial results for pharmaceutical and biotech firms.

Other key players in the market include Deep6.ai, Innoplexus, Intelligencia AI, Median Technologies, and Consilx.

Key Questions Answered in the AI in Clinical Trials Market Report

• What was the AI in clinical trials market value in 2024?
• What is the AI in clinical trials market forecast outlook for 2025-2034?
• What are the regional markets covered in the report?
• What is the market segmentation based on application?
• What is the market segmentation based on phase?
• What is the market breakup based on the end user?
• What are the major factors aiding the AI in clinical trials market demand?
• How has the market performed so far and how is it anticipated to perform in the coming years?
• What are the major drivers, opportunities, and restraints in the market?
• What are the major trends influencing the market?
• Which regional market is expected to dominate the market share in the forecast period?
• Which country is likely to experience elevated growth during the forecast period?
• Who are the key players involved in the AI in clinical trials market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

This product will be delivered within 3-5 business days.